OCA Ventures

Our Founder and CEO, Dr. Jo Varshney, has been named to Inc.’s 2026 Female Founders 500. We couldn’t be prouder. Dr. Varshney founded VeriSIM Life on a conviction that the gap between animal experiments and human biology should no longer determine whether a medicine succeeds or fails. That conviction led her to build BIOiSIM®, our translational AI platform that helps pharma and biotech teams predict drug safety, efficacy, and dosing before a single patient enters a clinical trial. Inc. specifically recognized Dr. Varshney for validating the predictive accuracy of our AI-powered drug development platform and initiating health-system partnerships that are redefining how medicines reach patients. Under her leadership, VeriSIM Life has raised over $25M, built a robust therapeutic pipeline, and advanced our lead drug candidate toward its first human clinical studies. None of it happens without the team behind the science and technology, and none of it matters unless it gets better therapies to patients faster. That’s the mission. That’s what drives us. Congratulations, Dr. Varshney. #FemaleFounders500 #AIinDrugDevelopment #BIOiSIM #VeriSIMLife #WomenInAI #DrugDevelopment #BioTech #HealthTech

"In terms of the ability for Atalan to use such large data sets from different data sources — that has been a really valuable tool for us, because from a health system standpoint, it's impossible to catch all of these potential stressors that are out there on our own or manually or even through dashboards. It's a challenge. Atalan essentially provides our market and on-the-ground leaders with proactive, actionable data that they can use. And this goes back to your AI point as well, in that the most valuable AI tools are the ones that actually generate value and actionable insights." Cyril Philip shared an important insight that the most valuable AI tools for health systems are those that generate actionable insights. Actionable insights has always been the guiding principle for me and Sisi since we co-founded Atalan. Our mission is to leverage technology to connect the dots across noisy data and surface the signals that are mission critical for health systems in real time so that clinicians are protected. https://lnkd.in/eVP7CufT

Honored to share the news that Amplified Sciences, Inc. has been selected as a finalist in the CANCER FUND Impact Investments™ last investment cycle of the year. We are one of five companies selected 🎊 — out of 238 evaluated — to advance to the final steps of the Pancreatic Cancer Investment Cycle for the next investment they plan to make through Cancer Fund 1. We celebrate this as a testament to the hard work our team has done to deliver the innovative test #PanCystPro serving an important clinical need. Clearly, the CANCER FUND Impact Investments™ community recognizes the importance of early detection in high risk patients for pancreatic cancer. Want to learn more interested, check out this link: https://lnkd.in/g-kN-_Ec and be sure to show interest soon – this stage of the cycle closes on December 11th. Anthony Bajoras Jeff Rea Jacob Rayyan #PancreaticCancer #DiagnosticsIsPower #EarlyDetection #oncologystartups 👉 https://lnkd.in/g-kN-_Ec

Hubly Auto-Stop Drill has received FDA 510(k) Clearance for Spine Decompression Surgery: Laminectomy & Laminotomy! Hubly Surgical's technology has been used to save many thousands of neurosurgical patient lives since our 2024 cranial launch. Now, the Hubly SMART auto-stop with mechanical plunge prevention will protect patients' brains AND spinal cords nationwide. "Today's clearance marks a pivotal step for Hubly's platform," said Casey Qadir, Founder & CEO of Hubly Surgical. "Our goal is to save and improve lives by giving surgeons intuitive tools that protect critical tissue every single time. With cranial and spinal indications now in hand, we can support neuro-spine teams across the board. One consistent, safe device experience across settings and use cases." Read more: https://lnkd.in/ecW6QR4W

📣 Today, we’re celebrating a major milestone: Alembic Technologies has raised a $145M Series B led by Accenture and Prysm Capital with participation from WndrCo, Liquid 2 Ventures, NextEquity Partners, Friends & Family Capital, and SLW. Alembic is scaling its Causal AI engine across the Fortune 500, enabling companies like Delta Air Lines , Mars, and NVIDIA to make billion-dollar decisions on proof, not probability. Generative AI changed how enterprises create. Predictive AI changed how enterprises forecast. Now, Causal AI changes how enterprises decide. For decades, enterprises have relied on correlation and simple dashboards that show what moved, not what caused the movement. Alembic’s Causal AI replaces guesswork with verifiable cause-and-effect truth. It isolates why revenue, engagement, or operational KPIs shift, allowing leaders to act with clarity instead of instinct. The era of blind analysis is over. #CausalAI #EnterpriseIntelligence #DigitalTransformation Link to the news: https://lnkd.in/g4e8yXZ5?